Adherex Technologies (FENC)
(Delayed Data from NSDQ)
$7.84 USD
-0.34 (-4.16%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $7.88 +0.04 (0.51%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FENC 7.84 -0.34(-4.16%)
Will FENC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FENC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FENC
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why
FENC: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Joint Misses Q1 Earnings Estimates on Rising Expenses
Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions
Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates
Other News for FENC
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC)
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC)
Fennec management to meet with Craig-Hallum
Fennec Pharmaceuticals Approves Proposals at Shareholder Meeting
Fennec Announces Results of Annual Meeting | FENC Stock News